

AMENDED CLAIMS

received by the International Bureau on 05 April 2005 (05.04.2005)

original claims 1-8, replaced by amended claims 1-8

1. The use of hyaluronic acid having molecular weight from 500 000 to 4 000 000 g/mol for manufacturing a dietetic preparation for prevention and treatment of osteoporosis, characterized in that it contains at least one physiologically acceptable salt of hyaluronic acid, which is in the form suitable for oral administration.
2. The use of hyaluronic acid of claim 1 for manufacturing a dietetic preparation for prevention and treatment of osteoporosis, characterized in that the physiologically acceptable salt of hyaluronic acid is selected from the group comprising sodium salt, potassium salt, zinc salt, magnesium salt or calcium salt.
3. Dietetic preparation according to claims 1 and 2 characterized in that it contains calcium salt.
4. Dietetic preparation according to claims 1 to 3 characterized in that the form suitable for oral administration contains 5 to 300 mg of physiologically acceptable salt of hyaluronic acid per day.
5. Dietetic preparation according to claims 1 to 4 characterized in that it further contains some victual.
6. Dietetic preparation according to claim 5 characterized in that the victuals are selected from the group comprising coconut flour, dried milk, inverted syrup, vitamin premix, de-mineralized water, chewing substance or fruit flavour.
7. Dietetic preparation according to any of the preceding claims characterized in that it is in solid form, such as tablets, bars, chewing tablets, chewing gum, hard capsules, or candies.
8. Dietetic preparation according to any of claims 1 to 6 characterized in that the dietetic preparation is in liquid form, such as an instant drink or syrup, wherein it further contains potassium sorbate as preservative.

Statement under Article 19(1)

Amended claims 1 - 8

Claims 1 and 2 were reworded to the. The expression “dietetic preparation for prevention and treatment of osteoporosis” in claims 1 and 2 was replaced by the expression “the use of hyaluronic acid...for manufacturing a dietetic preparation for prevention and treatment of osteoporosis” since the use of hyaluronic acid in therapy is known. The application claims a new way of the use of hyaluronic acid in therapy. Claims 3-5 remain unchanged.